Efficacy and safety of momelotinib in Janus kinase inhibitor experienced Asian patients with myelofibrosis and anemia

In a post hoc subgroup analysis of 17 Asian patients with myelofibrosis enrolled in the MOMENTUM trial, treatment with momelotinib was associated with improvements in symptom burden, anemia measures, and spleen response. The safety profile was generally favorable, with fewer high-grade adverse events observed in the momelotinib group compared with danazol.